Perceptions and Barriers to Outpatient Antiviral Therapy for COVID-19 and Influenza as Observed by Infectious Disease Specialists in North America: Results of an Emerging Infections Network (EIN) Survey, February 2024

Jordan B Singleton; Dennis Wang; Souci Louis; Dallas J Smith; Anastasia S Lambrou; Susan E Beekmann; Claire M Midgley; Philip Polgreen; Shikha Garg; Jessica N Ricaldi; Timothy M Uyeki; Scott Santibañez; Pragna Patel

doi:10.1093/ofid/ofae666

Perceptions and Barriers to Outpatient Antiviral Therapy for COVID-19 and Influenza as Observed by Infectious Disease Specialists in North America: Results of an Emerging Infections Network (EIN) Survey, February 2024

Open Forum Infect Dis. 2024 Nov 8;11(12):ofae666. doi: 10.1093/ofid/ofae666. eCollection 2024 Dec.

Affiliations

¹ Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² University of Iowa Carver College of Medicine, Department of Internal Medicine, Iowa City, Iowa, USA.

Abstract

Antiviral therapy is underutilized for outpatients at increased risk for severe COVID-19 or influenza. Results from this survey offer insights into treatment barriers from the infectious disease specialist perspective. Further education is needed about the benefits of early antiviral therapy.

Keywords: COVID-19; antivirals; barriers; influenza; treatment.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.